NeuraLight, a healthtech company providing precision biomarkers quantifying change in brain function, today announced a new ...
This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA.
Federally funded research suggests that standardizing what defines contamination could increase accuracy of diagnoses, optimize treatments, avoid unnecessary medications and improve patient outcomes ...
Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study. TACE with or without ...